Immunosuppressant methotrexate (MTX) had been widely used in the treatment of psoriasis vulgaris (Cribbs et al., 2015; Gladman, 2017), which returned to the normal function of peripheral blood regulatory T cells in plaque psoriasis via the AMPK/CD73/mTOR pathway (Yan et al., 2018). The gene discussed is MTOR; the disease is psoriasis vulgaris.